Inotek Pharmaceuticals Corp. (ITEK) Stock Price Down 1.5%
Shares of Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) fell 1.5% during mid-day trading on Friday . The stock traded as low as $7.03 and last traded at $7.06, with a volume of 77,045 shares changing hands. The stock had previously closed at $7.17.
Several research firms have issued reports on ITEK. Canaccord Genuity reissued a “buy” rating on shares of Inotek Pharmaceuticals Corp. in a research note on Saturday, May 14th. Piper Jaffray Cos. reissued a “buy” rating on shares of Inotek Pharmaceuticals Corp. in a research note on Thursday, May 12th.
The firm’s 50-day moving average is $7.56 and its 200 day moving average is $8.06. The company’s market capitalization is $192.01 million.
Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.07. On average, equities analysts expect that Inotek Pharmaceuticals Corp. will post ($1.42) earnings per share for the current fiscal year.
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.